How Is Thyroid Cancer Recurrence Checked? (2026 Guide)

Thyroid cancer recurrence is monitored through regular neck ultrasounds and blood tests (thyroglobulin and its antibody, TSH), and for those who have undergone total thyroidectomy, thyroglobulin level becomes the single most important marker.

Key Takeaways

• Thyroid cancer is known for sometimes recurring late, which is why follow-up continues over a long period — neck ultrasound and blood tests (thyroid hormone, TSH, thyroglobulin and its antibody) are repeated at set intervals after surgery.
• For patients who had a total thyroidectomy, thyroglobulin serves as the key marker for detecting recurrence, while medullary thyroid cancer is tracked instead using calcitonin and CEA.
• Monitoring is more frequent in the first 1-2 years, and intervals are gradually extended once results remain stable; patients classified as lower recurrence risk are followed less often, while higher-risk patients are followed more closely.
• Korea's 5-year relative survival rate for thyroid cancer is 100.2% (National Cancer Registration Statistics 2019-2023, Korea) — this is a nationwide statistic, not a prediction of any individual's outcome.
• If metastasis capable of absorbing radioactive iodine is suspected, a whole-body radioactive iodine scan may also be performed.

What Specific Tests Are Used to Check for Recurrence?

• The core tools are neck ultrasound and blood tests, with imaging studies added as needed.
• Neck ultrasound checks the surgical site and surrounding lymph nodes for any new nodules or enlarged lymph nodes. Blood tests measure thyroid hormone and TSH along with thyroglobulin and thyroglobulin antibody.
• Thyroglobulin is a protein produced by thyroid cells; after total thyroidectomy and radioactive iodine treatment, it should normally be almost undetectable in the body. A rising level again signals possible recurrence or remaining thyroid tissue.
• Because medullary thyroid cancer does not absorb iodine, calcitonin and CEA levels are tracked instead of thyroglobulin.
• When metastasis that absorbs radioactive iodine is suspected, a whole-body radioactive iodine scan is used to check for remaining tissue or metastasis throughout the body.

How Often and in What Order Are These Tests Performed?

• Step 1: After surgery and, if needed, radioactive iodine treatment, the first follow-up test schedule is set.
• Step 2: In the first 1-2 years, neck ultrasound and blood tests are repeated more frequently to closely track any changes.
• Step 3: Once results remain stable, testing intervals are gradually extended. Patients with lower recurrence risk classification are followed at longer intervals, while those with higher risk are kept on shorter intervals.
• Step 4: Patients who had total thyroidectomy have their hormone dosage adjusted — a higher-risk patient's dose is managed to keep TSH suppressed at a low level, while a lower-risk patient's dose is managed to maintain TSH within the normal range.
• Step 5: After returning home, many patients continue hormone dose adjustments and routine ultrasounds locally, based on a written opinion (handover summary) noting the next test schedule and target TSH range.

FAQ — If Recurrence Is Suspected, Is Repeat Surgery Done Right Away?

A suspicious finding does not automatically mean repeat surgery; the approach depends on the location, size, and tissue type involved. Small changes may simply be monitored with shorter follow-up intervals, radioactive iodine treatment may be considered if the metastasis absorbs iodine, and selective methods such as radiofrequency ablation or ethanol injection may be used for recurrent lymph nodes that are difficult to operate on. The appropriate approach is determined by the treating medical team based on a comprehensive review of test results.

FAQ — Can Follow-Up Testing Continue After Returning Home?

Hormone dose adjustment and routine ultrasound follow-up are generally easy to continue locally after returning home. A common approach is to receive a written opinion noting the next test schedule and target TSH range so that local physicians can reference it. However, for cases like medullary thyroid cancer that require tracking calcitonin and CEA together, or cases with higher recurrence risk, it is advisable to discuss the specific test items and intervals with the treating medical team in advance.

Sources and Notes

• This article was written based on notes on thyroid cancer and post-treatment follow-up testing (National Cancer Information Center, National Cancer Center Korea, NCCN patient guidelines, National Cancer Registration Statistics 2019-2023, SEER).
• This content is intended for general medical information purposes only; actual diagnosis, treatment methods, and outcomes may vary depending on individual condition. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.